investors
ECI exists at the intersection between hematology/transfusion medicine and multiple medical specialties ranging from ophthalmology to trauma care.
We are focused on a development pipeline that includes drug candidates that will meet critical needs and alleviate suffering, and we’re glad to have you partner with us on making these advances a reality.
ECI has been issued robust patents protecting the formulation that combines serum-like plasma with a novel antimicrobial molecule (chitosan) to create products ranging from liquid eye drops to healing gels, ointments, contact lenses, contoured bandages and wound dressings.
eci - at a glance
- biopharma company
- developing treatments for Dry Eye Disease, wound healing, mucosal membrane dryness and more, all leveraging ECI’s chitosan, and human plasma
- novel chitosan molecule (delivery, viscosity, sterility)
- patents: US (2021) / Japan (2022) / EU (pending) / Canada (pending)
- experienced team (intersection: eye/blood/chemistry)
the need
- 22 million dry eye patients in the US alone
- 500 million adults with diabetes at risk of hard-to-heal wounds
- ~10% of individuals and 25% of older people experience dry mouth
- >50% of postmenopausal individuals experience gynecologic dryness
the market
- $3.1 billion dry eye (US market)
- $24.5 billion wound care
- $600 million dry mouth
- $32 million gynecologic dryness
dry eye disease
dry eye disease
Treatments: Dry eye is caused by several conditions. Primary treatment is using an eye drop. However, side effects caused by eye drops, such as blurred vision, increased sensitivity, watering eyes, redness, swelling of eyelids, sticky eyelashes, and discomfort decrease adoption.
Farrand KF et al. AJO (2017), Dubey VD et al. IOVS (2010), Lum et al. AA of Optometry (2018)
ECI believes it is likely that serum eye drops will have fewer side effects. This belief is based on experience with autologous serum drops.
global dry eye treatment market size and projected growth
Coherent Market Insights, July 2020
learn more about:
our products
Our therapeutic formulation is suitable for a variety of products, including liquid eye drops, gels, ointments, contact lenses, contoured bandages, and wound dressings. We believe this formulation will promote healing of epithelial (surface cell) disorders, such as dry eye disease, ophthalmic burns, and chronic wounds.
our platform
Our platform leverages plasma from donated human blood and a proprietary antimicrobial molecule (form of chitosan). The tissue-repairing benefits of plasma-derived products, combined with the sustained action of chitosan, may provide relief and long-lasting therapeutic action.
our team
Our small team is comprised of experts in hematology, ophthalmology, biomedical/biomaterial engineering, quality/regulatory affairs, project management, drug design, pre-clinical trials, and device development.
We like dogs, hiking, swimming, sailing, making sushi, espresso, baking, and reading. And eyes, blood and science, of course!